Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab for bone health and skeletal-related event prevention in multiple myeloma
jRCT1061260069Recruiting
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of romosozumab in multiple myeloma (MM) and osteoporosis. Primary endpoint: Change in bone mineral density. Started Sep 2026; status: recruiting.
02
Drugs
romosozumab
03
Conditions
multiple myeloma (MM)osteoporosis
Beyond the preview
Go deeper on jRCT1061260069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061260069.